Faslodex
FDA approves AstraZeneca’s Truqap plus Faslodex for breast cancer treatment
November 17, 2023Medical Communications AstraZeneca, FDA, Faslodex, Oncology, breast cancer
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Truqap (capivasertib) in combination with Faslodex (fullvestrant) …
Pfizer’s Ibrance combo fails to improve overall survival in HER2- metastatic breast cancer
June 26, 2018Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Faslodex, Pfizer, breast cancer, ibrance, pharma
Pfizer has stumbled with the reveal of new data on the efficacy of its oral CDK 4/6 inhibitor Ibrance (palbociclib) in combination …
Faslodex rejected by NICE for NHS breast cancer use
February 2, 2018Research and Development, Sales and Marketing AstraZeneca, Faslodex, NHS, NICE, UK, pharma
Bad news for breast cancer patients in the UK as the National Institute for Health and Care Excellence announces it …
NICE rejects AstraZeneca’s breast cancer drug Faslodex
September 1, 2017Medical Communications, Sales and Marketing AstraZeneca, Cancer, Faslodex, breast cancer, life sciences, pharma, pharmaceutical
NICE has announced its decision to not recommend AstraZeneca’s breast cancer drug Faslodex (fulvestrant) in women who have oestrogen-receptor-positive, locally …
AstraZeneca’s Faslodex gets US FDA nod in combination treatment for breast cancer
March 8, 2016Manufacturing and Production, Research and Development AstraZeneca, Faslodex, US FDA, palbociclib
UK drug-maker AstraZeneca said the US Food and Drug Administration (FDA) has approved a new indication expanding the use of …
Pfizer breast cancer drug delivers
June 1, 2015Sales and Marketing ASCO, AZ, Faslodex, Pfizer, breast cancer, brett wells
A Phase III study on Pfizer’s treatment Ibrance in combination with hormone therapy has revealed the drug more than doubled …
NICE rejects AstraZeneca’s breast cancer drug
December 14, 2011Sales and Marketing AstraZeneca, Faslodex, NICE
NICE has made its final decision not to recommended AstraZeneca’s breast cancer drug Faslodex, as it says the drug is …
NICE won’t back Faslodex in breast cancer
November 10, 2011Sales and Marketing AstraZeneca, Faslodex, NICE
NICE has not recommended AstraZeneca’s breast cancer drug Faslodex as it says the drug is no better than existing treatments. …
NICE blames Faslodex rejection on uncertainties in AZ data
August 23, 2011Sales and Marketing AstraZeneca, Faslodex, NICE, breast cancer
NICE has not recommended a high-dose form of AstraZeneca’s breast cancer drug Faslodex because of uncertainties over its cost-effectiveness. In …
European approval for ‘double strength’ Faslodex
March 19, 2010Sales and Marketing AstraZeneca, Faslodex, breast cancer
AstraZeneca’s Faslodex has expanded its European licence after winning approval to treat women with hormone receptor-positive breast cancer in a …
Faslodex launched in UK
May 19, 2004AstraZeneca, Faslodex
The latest addition to AstraZeneca’s oncology franchise, breast cancer drug Faslodex has been launched in the UK.Licensed for the treatment …
Latest content
FibroFind appoints Lee Borthwick as CEO
